SG11201903411YA - Anti-p53 antibodies - Google Patents
Anti-p53 antibodiesInfo
- Publication number
- SG11201903411YA SG11201903411YA SG11201903411YA SG11201903411YA SG11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- international
- polypeptide
- agency
- antibodies
- Prior art date
Links
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 102000002933 Thioredoxin Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000013517 stratification Methods 0.000 abstract 1
- 229940094937 thioredoxin Drugs 0.000 abstract 1
- 108060008226 thioredoxin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 0111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/074978 Al 26 April 2018 (26.04.2018) WIP0 I PCT _ (51) (21) (22) (25) Filing Language: (26) (30) (71) International Patent Classification: (SG). LANE, David P; c/o Agency for Science, Technol- C07K16/18 (2006.01) A61P 35/00 (2006.01) ogy and Research, 1 Fusionopolis Way, #20-10 Connexis, A61K 39/395 (2006.01) A61K 38/17 (2006.01) Singapore 138632 (SG). HWANG, Le-Ann; c/o Agency A61K 48/00 (2006.01) GO1N 33/577 (2006.01) for Science, Technology and Research, 1 Fusionopolis Way, International Application Number: #20-10 Connexis, Singapore 138632 (SG). KOH, Xin Yu; c/o Agency for Science, Technology and Research, 1 Fu- PCT/SG2017/050522 sionopolis Way, #20-10 Connexis, Singapore 138632 (SG). International Filing Date: WAH, Liew Oi; c/o National University of Singapore, 11 17 October 2017 (17.10.2017) Hospital Drive, Singapore 169610 (SG). English (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore Publication Language: English 903031 (SG). Priority Data: (81) Designated States (unless otherwise indicated, for every 1617564.8 17 October 2016 (17.10.2016) GB kind of national protection available): AE, AG, AL, AM, Applicants: AGENCY FOR SCIENCE, TECHNOLO- AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, #20-10 Connexis North Tower, Singapore 138632 (SG). DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, SINGAPORE HEALTH SERVICES PTE LTD [SG/ ]; HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 31 Third Hospital Avenue, #03-03, Bowyer Block C, Singa- KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, pore 168753 (SG). NATIONAL UNIVERSITY OF SIN- MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, GAPORE [SG/ ]; 21 Lower Kent Ridge Road, Singapore OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 119077 (SG). SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Inventors: SABAPATHY, Tr Kanaga; c/o National Can- cer Centre Singapore, 11 Hospital Drive, Singapore 169610 (72) — = — = = Title: ANTI-P53 ANTIBODIES R175H (57) : The invention relates to methods for producing an antibody which is specific for a mutant p53 polypeptide over wildtype p53 polypeptide, comprising using said mutant p53 polypeptide as an immunogen wherein said polypeptide comprises: (i) an antigen sequence, E comprising an amino acid sequence of the mutant p53 polypeptide including the mutation and (54) = = — , , N. at least one amino acid immediately adjacent to the mutation, and (ii) a scaffold sequence for providing the antigen sequence in a solvent-accessible configuration, in particular wherein ‘ I I \"\" the scaffold sequence is thioredoxin. In the specific embodiments, antibodies against mutant p53 comprising R175H, R248Q or R273H are generated. Also disclosed are the uses of said antibodies for diagnosis, prognosis and stratification of patient groups and further encompasses R248Q the use of antibodies for imaging and treatment of cancer. = = = _ _ = = = = = ,N.e,s R273H ,1 Il GC IN 71' 0 66 Il © ei ,g,,LE(EF_rANLA , BJFIZT , Iilf P C [Continued on next page] WO 2018/074978 Al MIDEDIMOMOIDEIREEMOOVEHROMEMOVOIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2 (a) (viii))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617564.8A GB201617564D0 (en) | 2016-10-17 | 2016-10-17 | Anti-p53 antibodies |
| PCT/SG2017/050522 WO2018074978A1 (en) | 2016-10-17 | 2017-10-17 | Anti-p53 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903411YA true SG11201903411YA (en) | 2019-05-30 |
Family
ID=57680660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903411YA SG11201903411YA (en) | 2016-10-17 | 2017-10-17 | Anti-p53 antibodies |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11613568B2 (en) |
| EP (1) | EP3526251A4 (en) |
| JP (1) | JP7173964B2 (en) |
| CN (1) | CN110770252A (en) |
| GB (1) | GB201617564D0 (en) |
| SG (1) | SG11201903411YA (en) |
| WO (1) | WO2018074978A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3547845B1 (en) * | 2016-12-27 | 2023-03-01 | Hill's Pet Nutrition, Inc. | Pet food compositions |
| GB202008688D0 (en) | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN113403286B (en) * | 2021-06-24 | 2024-01-16 | 新乡学院 | Targeting three-display phage and preparation method and application thereof |
| WO2023060115A1 (en) * | 2021-10-05 | 2023-04-13 | The Penn State Research Foundation | Methods for treating cancers with mutated p53 |
| WO2023114430A1 (en) * | 2021-12-16 | 2023-06-22 | The Johns Hopkins University | Manabodies targeting p53 tumor antigens and methods of using |
| CN114574524A (en) * | 2022-03-14 | 2022-06-03 | 深圳市体内生物医药科技有限公司 | Method for screening liver cancer suppressor gene from whole genome and application thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083709A (en) | 1985-08-21 | 2000-07-04 | Osi Pharmaceuticals, Inc. | Immunoassay for detection of mutant P53 polypeptide in serum |
| WO1992013970A1 (en) * | 1991-02-01 | 1992-08-20 | Oncogene Science, Inc. | Immunoassay for detection of mutant p53 polypeptide in biological fluids |
| CA2064555A1 (en) | 1990-06-27 | 1991-12-28 | Arnold J. Levine | Probes for detecting mutant p53 |
| US5646016A (en) * | 1991-02-06 | 1997-07-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules |
| EP0651653B1 (en) * | 1992-07-22 | 2004-03-10 | The Trustees Of Princeton University | p53 VACCINE |
| US20030086935A1 (en) | 1992-07-22 | 2003-05-08 | Levine Arnold J. | p53 vaccine |
| GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| WO2006100681A2 (en) | 2005-03-25 | 2006-09-28 | Ramot At Tel Aviv University Ltd. | Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| WO2010120514A2 (en) * | 2009-03-31 | 2010-10-21 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
| WO2013036208A1 (en) | 2011-09-09 | 2013-03-14 | Agency For Science, Technology And Research | P53 activating peptides |
-
2016
- 2016-10-17 GB GBGB1617564.8A patent/GB201617564D0/en not_active Ceased
-
2017
- 2017-10-17 SG SG11201903411YA patent/SG11201903411YA/en unknown
- 2017-10-17 US US16/342,763 patent/US11613568B2/en active Active
- 2017-10-17 WO PCT/SG2017/050522 patent/WO2018074978A1/en unknown
- 2017-10-17 JP JP2019520556A patent/JP7173964B2/en active Active
- 2017-10-17 EP EP17861395.6A patent/EP3526251A4/en active Pending
- 2017-10-17 CN CN201780078161.4A patent/CN110770252A/en active Pending
-
2023
- 2023-02-22 US US18/172,773 patent/US20230257457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11613568B2 (en) | 2023-03-28 |
| EP3526251A4 (en) | 2020-06-10 |
| JP7173964B2 (en) | 2022-11-16 |
| CN110770252A (en) | 2020-02-07 |
| US20190248879A1 (en) | 2019-08-15 |
| EP3526251A1 (en) | 2019-08-21 |
| JP2019535241A (en) | 2019-12-12 |
| GB201617564D0 (en) | 2016-11-30 |
| WO2018074978A1 (en) | 2018-04-26 |
| US20230257457A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903411YA (en) | Anti-p53 antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201810471YA (en) | T cell expansion | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201909466RA (en) | Human anti-semaphorin 4d antibody | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201910195WA (en) | Methods for trapping and barcoding discrete biological units in hydrogel | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies |